Literature DB >> 27460441

Mutated BRAF and personalised medicine in differentiated thyroid cancer.

Keith C Bible1, Mabel Ryder2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27460441     DOI： 10.1016/S1470-2045(16)30230-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.

Authors:  Zheming Lu; Yujie Zhang; Dongdong Feng; Jindong Sheng; Wenjun Yang; Baoguo Liu
Journal:  Oncotarget       Date:  2017-07-11

2.  Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.

Authors:  Youwen Zhu; Kun Liu; Kailing Wang; Libo Peng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

3.  Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma.

Authors:  Wei Chen; Yu Kun Luo; Ying Zhang; Qing Song; Jie Tang
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

4.  VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer.

Authors:  Sonam Choden; Somboon Keelawat; Chan Kwon Jung; Andrey Bychkov
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.